# TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

> **NCT00133887** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 77 (actual)

## Conditions studied

- Skin Cancer
- Kidney Transplantation

## Interventions

- **DRUG:** rapamycin
- **DRUG:** ciclosporine
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00133887
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2011-03
- **Final completion:** 2014-05
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133887, "TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00133887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*